Bacteriophage pharmacodynamics studied in an in vitro pharmacokinetic model of infection
Marie AttwoodiD, Pippa Griffin, Patryk Smorowinski, Alan R. Noel, Melissa EK HainesiD, Andrew D. MillardiD, Karen D. AdleriD, Martha R. J. ClokieiD, Alasdair P. MacGowaniD
Abstract
SynopsisO_ST_ABSBackgroundC_ST_ABSBacteriophage therapy offers an alternative way to counter the menace of increasing antimicrobial resistance. Despite its use in clinical practice for many decades the basic tools to study the translational pharmacodynamics of phages are not available and it is recognised that lack of understanding of phage pharmacokinetic/dynamics (PK/PD) is a severe limitation in individual patient use and clinical trial design. MethodsTraditional in vitro PK/PD evaluation tools were used to assess the antibacterial effect of single exposures of a bacteriophage cocktail against 4 strains of E. coli with potentially different patterns of response to phage. Initially, time-kill curves (TKC) were performed over 48hr and subsequently a dilutional in vitro model (IVM) was used to assess the antibacterial effects over 72hr. ResultsIn TKC, the four E. coli strains showed different patterns of kill and regrowth when exposed to phage with two strains showing a sustained drop in bacterial viable count and two showing initial kill and regrowth. Using the IVM similar bacterial pharmacodynamic patterns were observed, and phage titre increased inversely but consistently with E. coli kill. ConclusionsAn In vitro dilutional model can be used to study the antibacterial effect of a phage cocktail on E.coli showing strain-to-strain variation in bacterial killing and bacteriophage titre. Such models can be used to provide more nuanced information on phage pharmacokinetics/dynamics and translationally useful information for dosing in humans.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- FWCI
- 0.00
- Field percentile
- 24th percentile
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Combination of in vivo phage therapy data with in silico model highlights key parameters for treatment efficacy
R. Delattre, J. Seurat, … L. Debarbieux·bioRxiv·Mar 4, 2021
- Bridging in vitro and in vivo insights: A PKPD model for effective phage therapy against multidrug-resistant Pseudomonas aeruginosa
Jun Seok Cha, Kyungnam Kim, … Dongwoo Chae·mSystemsPeer-reviewed·Nov 13, 2025
- Second-order kinetics describe systemic clearance of therapeutic bacteriophages
Joël L. Gerber, David R. Cameron, … Yok‐Ai Que·bioRxiv·Aug 5, 2026
- Development of antibacterial drug plus bacteriophage combination assays
Marie Attwood, Pippa Griffin, … Alasdair P. MacGowan·JAC-Antimicrobial ResistancePeer-reviewed·Jul 3, 2024
- Optimizing the Timing and Composition of Therapeutic Phage Cocktails: A Control-theoretic Approach
G. Li, C. Y. Leung, … J. Weitz·bioRxiv·Nov 19, 2019
- The life history traits of phages in a cocktail determine coinfection dynamics and efficacy
Ruqaiyah Khan, Harshali V. Chaudhari, … Kiran R. Kondabagil·bioRxiv·Oct 26, 2024